
Sign up to save your podcasts
Or
In this podcast interview recorded at ASCO GU25, UROONCO bladder cancer chief editor Dr. Benjamin Pradere talked to Dr. Nadine Houede from CHU Nîmes, Hospital Caremeau in France, on the results of the iNDUCT trial.
The iNDUCT trial is a phase II trial evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. Dr. Houede discusses the rational, the results and next steps.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
3.7
33 ratings
In this podcast interview recorded at ASCO GU25, UROONCO bladder cancer chief editor Dr. Benjamin Pradere talked to Dr. Nadine Houede from CHU Nîmes, Hospital Caremeau in France, on the results of the iNDUCT trial.
The iNDUCT trial is a phase II trial evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. Dr. Houede discusses the rational, the results and next steps.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
7,809 Listeners
1,767 Listeners
316 Listeners
1,299 Listeners
480 Listeners
39 Listeners
2,412 Listeners
133 Listeners
57 Listeners
2 Listeners
0 Listeners
49 Listeners
0 Listeners
3,364 Listeners
0 Listeners